These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28955993)

  • 1. LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer.
    Jotatsu T; Yagishita S; Tajima K; Takahashi F; Mogushi K; Hidayat M; Wirawan A; Ko R; Kanemaru R; Shimada N; Mitani K; Saito T; Takamochi K; Suzuki K; Kohsaka S; Kojima S; Mukae H; Yatera K; Takahashi K
    Biochem Biophys Rep; 2017 Mar; 9():86-94. PubMed ID: 28955993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.
    Nguyen EM; Taniguchi H; Chan JM; Zhan YA; Chen X; Qiu J; de Stanchina E; Allaj V; Shah NS; Uddin F; Manoj P; Liu M; Cai SF; Levine R; Quintanal-Villalonga Á; Sen T; Chow A; Rudin CM
    J Thorac Oncol; 2022 Aug; 17(8):1014-1031. PubMed ID: 35691495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
    Coleman DJ; Sampson DA; Sehrawat A; Kumaraswamy A; Sun D; Wang Y; Schwartzman J; Urrutia J; Lee AR; Coleman IM; Nelson PS; Dong X; Morrissey C; Corey E; Xia Z; Yates JA; Alumkal JJ
    Neoplasia; 2020 Jun; 22(6):253-262. PubMed ID: 32403054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state.
    Yan W; Chung CY; Xie T; Ozeck M; Nichols TC; Frey J; Udyavar AR; Sharma S; Paul TA
    Mol Oncol; 2022 Mar; 16(6):1309-1328. PubMed ID: 34669238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1.
    Chen HY; Durmaz YT; Li Y; Sabet AH; Vajdi A; Denize T; Walton E; Laimon YN; Doench JG; Mahadevan NR; Losman JA; Barbie DA; Tolstorukov MY; Rudin CM; Sen T; Signoretti S; Oser MG
    Nat Commun; 2022 Aug; 13(1):4998. PubMed ID: 36008402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
    Takagi S; Ishikawa Y; Mizutani A; Iwasaki S; Matsumoto S; Kamada Y; Nomura T; Nakamura K
    Cancer Res; 2017 Sep; 77(17):4652-4662. PubMed ID: 28667074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of neuronal Lysine-Specific Demethylase 1LSD1/KDM1A impairs transcriptional repression by regulating interaction with CoREST and histone deacetylases HDAC1/2.
    Toffolo E; Rusconi F; Paganini L; Tortorici M; Pilotto S; Heise C; Verpelli C; Tedeschi G; Maffioli E; Sala C; Mattevi A; Battaglioli E
    J Neurochem; 2014 Mar; 128(5):603-16. PubMed ID: 24111946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
    Hiatt JB; Sandborg H; Garrison SM; Arnold HU; Liao SY; Norton JP; Friesen TJ; Wu F; Sutherland KD; Rienhoff HY; Martins R; Houghton AM; Srivastava S; MacPherson D
    Clin Cancer Res; 2022 Oct; 28(20):4551-4564. PubMed ID: 35920742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of LSD1 inhibitors in lung cancer.
    Mohammad HP; Kruger RG
    Mol Cell Oncol; 2016 Mar; 3(2):e1117700. PubMed ID: 27308632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the LSD1/KDM1 Family of Lysine Demethylases in Cancer and Other Human Diseases.
    Mao F; Shi YG
    Adv Exp Med Biol; 2023; 1433():15-49. PubMed ID: 37751134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A specific LSD1/KDM1A isoform regulates neuronal differentiation through H3K9 demethylation.
    Laurent B; Ruitu L; Murn J; Hempel K; Ferrao R; Xiang Y; Liu S; Garcia BA; Wu H; Wu F; Steen H; Shi Y
    Mol Cell; 2015 Mar; 57(6):957-970. PubMed ID: 25684206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted drugs in small-cell lung cancer.
    Santarpia M; Daffinà MG; Karachaliou N; González-Cao M; Lazzari C; Altavilla G; Rosell R
    Transl Lung Cancer Res; 2016 Feb; 5(1):51-70. PubMed ID: 26958493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest.
    Jin Y; Ma D; Gramyk T; Guo C; Fang R; Ji H; Shi YG
    Biochem Biophys Res Commun; 2019 Jul; 515(1):214-221. PubMed ID: 31146914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic compounds targeting pharmacological target lysine specific demethylase 1 and its impact on immunotherapy, chemotherapy and radiotherapy for treatment of tumor recurrence and resistance.
    Agboyibor C; Dong J; Effah CY; Drokow EK; Ampomah-Wireko M; Pervaiz W; Sangmor A; Ma X; Li J; Liu HM; Zhang P
    Biomed Pharmacother; 2023 Jan; 157():113934. PubMed ID: 36395607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer.
    Lv T; Yuan D; Miao X; Lv Y; Zhan P; Shen X; Song Y
    PLoS One; 2012; 7(4):e35065. PubMed ID: 22493729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LSD1 Inhibition Attenuates Tumor Growth by Disrupting PLK1 Mitotic Pathway.
    Dalvi PS; Macheleidt IF; Lim SY; Meemboor S; Müller M; Eischeid-Scholz H; Schaefer SC; Buettner R; Klein S; Odenthal M
    Mol Cancer Res; 2019 Jun; 17(6):1326-1337. PubMed ID: 30760542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative splicing of the histone demethylase LSD1/KDM1 contributes to the modulation of neurite morphogenesis in the mammalian nervous system.
    Zibetti C; Adamo A; Binda C; Forneris F; Toffolo E; Verpelli C; Ginelli E; Mattevi A; Sala C; Battaglioli E
    J Neurosci; 2010 Feb; 30(7):2521-32. PubMed ID: 20164337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).
    Li Z; Ding L; Li Z; Wang Z; Suo F; Shen D; Zhao T; Sun X; Wang J; Liu Y; Ma L; Zhao B; Geng P; Yu B; Zheng Y; Liu H
    Acta Pharm Sin B; 2019 Jul; 9(4):794-808. PubMed ID: 31384539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1.
    Wirawan A; Tajima K; Takahashi F; Mitsuishi Y; Winardi W; Hidayat M; Hayakawa D; Matsumoto N; Izumi K; Asao T; Ko R; Shimada N; Takamochi K; Suzuki K; Abe M; Hino O; Sekido Y; Takahashi K
    Mol Cancer Res; 2022 Jan; 20(1):127-138. PubMed ID: 34593606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.